Meeting Banner
Abstract #4729

PEG-FGF21 Variant Improves Hepatic Steatosis in a Mouse Model of NASH as Determined by Quantitative Water-fat MRI

Haiying Tang1, Matthew Fronheiser1, Stephanie Boehm2, Adrienne Pena1, Shorts Andrea1, Bradley Zinker2, John Krupinski2, Harold Malone1, Patrick Chow1, Edgar Charles1, Shuyan Du1, and Wendy Hayes1

1Bristol-Myers Squibb, Lawrenceville, NJ, United States, 2Bristol-Myers Squibb, Hopewell, NJ, United States

Non-alcoholic fatty liver disease (NAFLD) ranges from simple fatty liver to steatohepatitis (NASH) to cirrhosis. In the present study, we implemented a water-fat MRI using the gradient-reversal technique to quantify the hepatic proton density fat-fraction (PDFF), for assessment of hepatic steatosis in a diet-induced mouse model of NASH. We compared the quantitative water-fat MRI technique with conventional Dixon method and single-voxel MR spectroscopy (MRS), and correlated the MRI-PDFF with histology and biochemical triglyceride (TG) content. Lastly, the effects of a PEGylated-FGF21 variant (PEG-FGF21v) on hepatic steatosis in the mouse model was evaluated using the water-fat MRI technique.

This abstract and the presentation materials are available to members only; a login is required.

Join Here